Expand RYTM Menu
RYTM MENU

RYTM Latest Press Releases

-- July 8, 2026 --

Rhythm Pharmaceuticals Announces The New England Journal of Medicine Publication of Phase 3 TRANSCEND Trial Results in Acquired Hypothalamic Obesity Globe Newswire 5:07 PM

-- June 15, 2026 --

Rhythm Pharmaceuticals Announces Multiple New Data Presentations from MC4R Agonists in Acquired Hypothalamic Obesity (HO), Bardet-Biedl Syndrome (BBS) and Prader-Willi Syndrome (PWS) at ENDO 2026 Globe Newswire 4:01 PM

-- June 13, 2026 --

Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Globe Newswire 8:01 AM

-- June 12, 2026 --

Rhythm Pharmaceuticals to Announce Interim Six-Month Phase 2 Results Evaluating Setmelanotide in Patients with Prader-Willi Syndrome Globe Newswire 4:01 PM

-- May 29, 2026 --

Rhythm Pharmaceuticals Announces Seven Abstracts Accepted for Presentation at ENDO 2026 Globe Newswire 8:00 AM

-- May 28, 2026 --

Rhythm Pharmaceuticals Announces Publication of New Bardet-Biedl Syndrome Diagnostic Algorithm in the American Journal of Medical Genetics Globe Newswire 8:00 AM

-- May 26, 2026 --

Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences Globe Newswire 8:00 AM

-- May 12, 2026 --

Rhythm Pharmaceuticals Announces New Data Presentations at the 2026 European Congress of Endocrinology Globe Newswire 8:00 AM

-- May 6, 2026 --

Rhythm Pharmaceuticals Announces Participation in Upcoming Bank of America Global Healthcare Conference Globe Newswire 8:00 AM

-- May 5, 2026 --

Rhythm Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update Globe Newswire 7:00 AM

-- May 4, 2026 --

Rhythm Pharmaceuticals Announces New Data Presentations in Acquired Hypothalamic Obesity at Pediatric Endocrine Society Globe Newswire 8:00 AM

-- May 1, 2026 --

Rhythm Pharmaceuticals Announces IMCIVREE (Setmelanotide) Granted Marketing Authorization by European Commission for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity Globe Newswire 6:55 AM

-- April 9, 2026 --

Rhythm Pharmaceuticals to Report First Quarter 2026 Financial Results on Tuesday, May 5, 2026 Globe Newswire 8:00 AM

-- April 3, 2026 --

Rhythm Pharmaceuticals Announces Changes to Board of Directors Globe Newswire 9:00 AM

-- March 26, 2026 --

Rhythm Pharmaceuticals Receives Positive CHMP Opinion for IMCIVREE (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity due to Hypothalamic Injury or Impairment Globe Newswire 9:01 AM

-- March 20, 2026 --

PANTHERx Rare Selected by Rhythm Pharmaceuticals Inc. as the Exclusive U.S. Specialty Pharmacy for the Expanded Indication for IMCIVREE (setmelanotide) PRNewswire 12:59 PM

-- March 19, 2026 --

Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE (setmelanotide) for Patients with Acquired Hypothalamic Obesity Globe Newswire 6:30 PM

-- March 16, 2026 --

Rhythm Pharmaceuticals Announces Topline Results from Phase 3 EMANATE Trial Globe Newswire 4:01 PM

-- March 1, 2026 --

Rhythm Pharmaceuticals Announces Additional Positive Data from Phase 3 TRANSCEND trial of Setmelanotide in Patients with Acquired Hypothalamic Obesity Globe Newswire 12:30 PM

-- February 26, 2026 --

Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update Globe Newswire 7:00 AM

-- February 17, 2026 --

Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 26, 2026 Globe Newswire 8:00 AM
Market Data Delayed 15 Minutes